1 “... treatment option. Based on these analyses, the Canadian Optimal Medication Prescribing and Utilization...”

2 “... treatment option. Based on these analyses, the Canadian Optimal Medication Prescribing and Utilization...”

3 “... the price of the inhaled corticosteroid (ICS) plus long-acting beta2 agonist (LABA) price and assuming...”

4

5

6

7

8 “... to price reductions in LMWH and the recent increases in the cost of UFH resulting from higher manufacturing...”

9 “... corticosteroid (ICS)/long-acting beta2-agonist (LABA) (ICS/LABA), less expensive options are available that could...”

10 “... for vortioxetine were based on the manufacturer's submitted price and unit drug prices for comparators were...”

11 “... was 0% at a threshold of $50,000 per QALY (and even at a threshold of $100,000 per QALY). Price...”

12 “... for vortioxetine were based on the manufacturer's submitted price and unit drug prices for comparators were...”

13 “.... In the CADTH reanalyses, at the submitted price, APO SL was less costly when compared with the list price...”

14 “..., and for which alternative treatment options are inadequate. Tapentadol ER tablets are available in 50 mg, 100 mg...”

15 “...In the csDMARD-IR population, the preferred option is csDMARD monotherapy if the decision-maker...”

16 “...In the csDMARD-IR population, the preferred option is csDMARD monotherapy if the decision-maker...”

17

18 “... cirrhosis. The manufacturer submitted a price of $714.29 per tablet, or $60,000 for a 12-week course...”

19 “... cirrhosis. The manufacturer submitted a price of $714.29 per tablet, or $60,000 for a 12-week course...”